

Supplemental Information

Excretion Patterns of Urinary Sediment and Supernatant Podocyte Biomarkers in Patients with Chronic Kidney Disease

^{1,2}Akihiro Fukuda, ²Akihiro Minakawa, ²Yuji Sato, ¹Hiroataka Shibata, ³Masanori Hara, ²Shouichi

Fujimoto

¹Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Japan

²Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

³Iwamuro Health Promotion Center, Niigata, Japan

Table of Contents

Supplemental Figure S1. Relationship between urinary podocyte markers and proteinuria in patients with MCNS.

Supplemental Table S1. Clinical parameters, urinary podocyte markers, with or without relapse, and use of immunosuppressive drugs in patients with MCNS.

Supplemental Figure S1.**Relationship between urinary podocyte markers and proteinuria in patients with MCNS.**

(A) Relationship between u-sed Pod mRNA excretion and proteinuria.



(B) Relationship between u-sup PCX protein and proteinuria.

U-sed Pod mRNA excretion, but not u-sup PCX protein, was significantly correlated with proteinuria

(U-sed Pod mRNA excretion: $n = 15$, $r = 0.61$, $p = 0.02$; U-sup PCX protein: $n = 15$, $r = -0.25$, $p = 0.37$).

Supplemental Figure S1.

Minimal change nephrotic syndrome



Supplemental Table S1.

Clinical parameters, urinary podocyte markers, with/without relapse, and use of immunosuppressive drugs in patients with MCNS

Pt No	Sex	Age	e-GFR	SBP	DBP	TP	Alb	U-Pro/Cre	logPodCR	logPCX	relapse	Immunosuppressive
			(mL/min/1.73m ²)	(mmHg)	(mmHg)	(g/dL)	(g/dL)	(g/gCr)				drug
1	F	59	54.5	143	86	3.93	1.29	7.17	5.55	5.71	-	-
2	M	22	104.9	136	82	4.03	1.41	1.00	2.56	4.15	-	PSL
3	M	52	62.4	106	61	4.58	1.32	5.03	4.06	3.73	+	-
4	F	72	23.7	60	42	4.37	1.21	18.86	6.37	5.88	-	PSL
5	F	71	29.7	105	62	3.99	1.05	9.21	3.18	5.02	-	-
6	F	50	66.8	132	79	3.54	1.31	2.77	3.92	4.27	+	-
7	M	35	59.4	135	85	4.28	1.79	12.41	2.67	4.87	+	-
8	F	77	27.9	99	52	4.5	1.61	6.07	1.66	1.91	-	-
9	F	64	60.4	135	84	3.87	1.38	11.69	N/A	3.51	+	PSL, MZR
10	M	67	67.6	94	59	6.17	1.97	0.47	4.27	5.89	+	PSL
11	M	71	9.2	150	76	4.82	1.51	12.52	3.94	4.68	+	-
12	M	67	32.1	110	77	4.47	1.6	5.26	1.97	3.66	+	-
13	F	28	98.1	111	80	3.89	1.76	1.94	1.94	3.82	+	PSL, TAC
14	M	36	59.0	135	85	4.28	1.79	0.02	-0.59	2.90	+	PSL
15	F	46	19.2	139	73	3.8	1.25	5.89	6.20	2.09	+	-

PSL, prednisolone; MZR, mizoribine; TAC, tacrolimus